Berzosertib Drug Asset Due Diligence Report 2026

This Berzosertib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Berzosertib can convert its Small molecule drug profile and ATR biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Berzosertib (query alias: berzosertib)
Modality / target	Small molecule drug; ATR; ATR inhibitors
Highest global status	Phase 2
Originator	Vertex Pharmaceuticals, Inc.
Active developers	National Cancer Institute, Merck Healthcare KGaA, Vertex Pharmaceuticals, Inc.

The MCP disease footprint includes Leiomyosarcoma, Soft Tissue Sarcoma, Neoplasms. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT04807816	Phase 2	Completed	58	Assessment of the antitumor activity of berzosertib combined with gemcitabine
NCT04802174	Phase 1/2	Active, not recruiting	37	MTD
NCT04826341	Phase 1/2	Active, not recruiting	35	Phase II: ORR

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Extrapulmonary small cell carcinoma treated with conventional or tumor-targeted topoisomerase I inhibition plus ATR blockade: Clinical outcomes and molecular correlates.

Phase 2; n=34; evaluation: Positive. Reported fields: AE(Grade 3-4) = Grade 3-4 hematologic adverse events were more frequent with topotecan+berzosertib, whereas gastrointestinal toxicity and alopecia were more common with SG+berzosertib ; AE(Grade 3-4) = Grade 3-4 hematologic adverse events were more frequent with topotecan+berzosertib, whereas gastrointestinal toxicity and alopecia were more common with SG+berzosertib

Phase 1/2 trial of ATR inhibitor berzosertib plus immune checkpoint inhibitor avelumab in patients with advanced cancers with DNA damage response (DDR) gene alterations: Tumor microenvironment–mediated pathways of resistance from correlative data.

Phase 1/2; n=17; evaluation: Positive. Reported fields: ORR = 12.5 %

Phase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine With or Without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer

Phase 1; n=35; evaluation: not stated. Reported fields: -; Dost Limiting Toxicity (DLT) (Phase I Dose Escalation) = 2 Participants ; -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Berzosertib addresses Leiomyosarcoma, Soft Tissue Sarcoma, Neoplasms. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2017-01-11	Merck KGaA has paid Vertex Pharmaceuticals $230 million upfront for the rights to four cancer programs.	Phase 2	US$230.0M upfront

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Targeting immune suppression after ATR inhibition”. The milestone feed surfaced a patent-application signal described as “Compound as ATR kinase inhibitor”. The milestone feed surfaced a patent-application signal described as “Application of ATR inhibitor VE-822 in treatment of lung adenocarcinoma”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO